IP Library Patent Application 12545120
Patent Application
App. No. 12/545,120

METHODS FOR CONCOMITANT ADMINISTRATION OF COLCHICINE AND A SECOND ACTIVE AGENT

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
12/545,120
Abstract

Methods for concomitant administration of colchicine together with one or more second active agents, e.g., atorvastatin, are disclosed. Such methods reduce the dangers commonly associated with such concomitant administration and provide additional benefits. Methods of notifying health care practitioners and patients regarding appropriate dosing for concomitant administration of colchicine together with second active agents are also provided.

Claims (16)

1 . A method of treating a patient with colchicine, comprising

orally administering an adjusted daily dosage amount of colchicine to the patient who is receiving concomitant administration of a daily dose of atorvastatin, wherein the atorvastatin is administered to treat an atorvastatin-responsive condition,

wherein the adjusted daily dosage amount of colchicine is about 50% to 75% of an intended daily dosage amount of colchicine, and

wherein the intended daily dosage amount of colchicine is a daily dosage amount suitable for the patient if the patient were not receiving concomitant atorvastatin, wherein concomitant administration of atorvastatin is administration either simultaneously with colchicine or within a time period during which the effects of the colchicine are still operative in the patient.

2 . The method of claim 1 , wherein treating with colchicine is treating chronic gout.

3 . The method of claim 1 , wherein treating with colchicine is treating for acute gout.

4 . The method of claim 1 , wherein treating with colchicine is treating familial Mediterranean fever.

5 . The method of claim 3 , wherein, the intended daily dosage amount is 1.8 mg/day and the adjusted daily dosage amount is 1.2 mg/day.

6 . The method of claim 5 , further comprising not repeating colchicine administration for at least three days.

7 . The method of claim 2 , wherein, the intended daily dosage amount is 1.2 mg/day and the adjusted daily dosage amount is 0.6 mg/day.

8 . The method of claim 2 , wherein, the intended daily dosage amount is 0.6 mg/day and the adjusted daily dosage amount is 0.6 mg every other day.

9 . The method of claim 1 , further comprising carefully monitoring the individual for potential toxicity.

10 . The method of claim 3 , wherein the intended daily dosage amount is 1.8 to 2.4 mg and the maximum adjusted daily dosage amount is 1.8 mg.

11 . The method of claim 4 , wherein the intended daily dosage amount is 1.2 to 2.4 mg and the maximum adjusted daily dosage amount is 0.6 mg.

12 . The method of claim 4 , wherein treating is for familial Mediterranean fever, the intended daily dosage amount is 0.9 to 1.8 mg and the maximum adjusted daily dosage amount is 0.6 mg.

13 . The method of claim 4 , wherein the intended daily dosage amount is 0.3 to 1.8 mg and the maximum adjusted daily dosage amount is 0.6 mg.

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded Aug 4, 2011
From: UBS AG, STAMFORD BRANCH, A SWISS BANKING INSTITUTION
To: MUTUAL PHARMACEUTICAL COMPANY, INC., A PENNSYLVANIA CORPORATION
Reel/Frame 026700/0240 →
PATENT SECURITY AGREEMENT Recorded Oct 26, 2009
From: MUTUAL PHARMACEUTICAL COMPANY, INC.
To: UBS AG, STAMFORD BRANCH, AS COLLATERAL AGENT
Reel/Frame 023424/0896 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 25, 2009
From: DAVIS, MATTHEW
To: MUTUAL PHARMACEUTICAL COMPANY, INC.
Reel/Frame 023140/0243 →